> ## Content Index
> Fetch the complete content index at: https://acentricresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regenerative scaffolds and tissue-engineering materials: Junction Brief – November 2026
- URL: https://acentricresearch.com/research/regenerative-scaffolds-brief-2026-11/
- Published: 2026-11-21T09:13:31.000Z
- Updated: 2026-11-21T09:43:43.000Z
- Author: Kevin Meyer
- Tags: biotechnology-materials, junction-brief

> Acentric Research is produced with AI tools under human review. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in [Biotechnology × Materials in the Landscape Report](https://acentricresearch.com/research/landscape-2026-11/#biotechnology-materials).

### Overview

A scaffold is a structure, made of a gel, a polymer, a ceramic or a mix, that gives cells something to grow on and can carry signals that guide them. The material sets the pore size, stiffness and breakdown rate, which decide whether cells move in and what they become. Here the material design is the main part of the therapy.

The stages differ widely. Federal programs support scaffold materials design and a goal-driven program on joint repair, and one company has registered and completed a safety study of a scaffold wound matrix. The dated sources opened run from 2023 to 2026, with the federal program launch from May 2023 and a funding round from March 2024; later developments were not searched.

### Current state

**Government programs.** NIBIB's Physiomimetic Materials program supports "the development and demonstration of broadly applicable physiomimetic materials to enable new paradigms of human health." The program's stated emphasis is materials and associated computational models for biomedical intervention, and its listed interests include electrically conductive and mechano-sensitive scaffolds for repairing tissue. \[1\] ARPA-H launched its NITRO program (Novel Innovations for Tissue Regeneration in Osteoarthritis) on 18 May 2023\. It named three areas: injectable bone regeneration, injectable cartilage regeneration and replacement joints built from human cells, and stated that multiple awards were anticipated. The page does not use the word scaffold; the link to scaffold materials is this Brief's reading. The award list and current status were not read. \[2\] ARPA-H says that for joints damaged beyond repair, current treatment is open-joint replacement surgery, typically with a titanium-alloy total joint, and that NITRO teams may pursue replacement joints built from a person's own cells, requiring no permanent hardware. \[2\]

**A company in its own words.** Tempo Therapeutics describes itself as an innovator in tissue engineering and regenerative medicine. Its platform, called Microporous-Annealed-Particle (MAP), is a synthetic tissue scaffold; the company says its lead product TT101 is for complex surgical sites with exposed bone, tendon or fascia, and announced a $12 million Series A round in March 2024 to take two lead scaffold candidates into clinical trials (company statements as reported by Pulse 2.0). \[3\] ClinicalTrials.gov lists a study of a MAP wound matrix, "Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds", with a start date of 26 August 2024 and a status of completed, as read on the access date. \[4\] The registry names Tempo Therapeutics as lead sponsor and describes a randomized, open-label safety evaluation of the TT101 device, a scaffold applied to clean wounds after skin cancer surgery, compared with a control, in 40 participants. Its primary outcome is the incidence of serious adverse device effects against the control group over 24 weeks, and the record gives a completion date of 30 July 2025 and posted results from 3 June 2026, which this Brief did not read. \[4\]

**Another example.** Nanochon is described, in a January 2026 news item relayed by a Northwestern University page, as a Washington, D.C. orthopedic device company developing implants for articular cartilage repair; its Chondrograft implant is "designed to treat knee cartilage defects by combining regenerative tissue technology with mechanical support", and the item reports $11.3 million raised in total. \[5\] The item gives no trial or regulatory status for Chondrograft.

**How far it has come.** The sources opened show one scaffold product through an early human safety study, and agency programs aimed at later stages. They contain no approval of a scaffold that regrows joint cartilage or bone. \[2\]\[4\] Scaffold-type products of other kinds are already cleared or approved. The same Northwestern page, relaying other reports, lists a July 2025 expanded 510(k) clearance for a synthetic bone graft, a July 2025 clearance for a self-assembling collagen scaffold and, citing FDA, a December 2025 approval of a nerve scaffold. \[5\] These are secondary relays, not FDA records.

### Opportunities

ARPA-H says there is no therapeutic that reverses osteoarthritis damage and that the condition affects more than 32 million Americans, with an estimated economic burden of more than $136 billion a year (its figures). \[2\] ARPA-H's program is aimed at that gap; whether scaffolds are part of the solutions it funds was not checked. NIBIB's interest in conductive and mechano-sensitive scaffolds points to materials that respond to the tissue around them. \[1\] What would show progress is a registered study of tissue regrowth, not only of safety.

### Challenges

- **Biology and engineering.** A scaffold must carry load or fit the wound, break down as new tissue forms, and not provoke harmful reactions. ARPA-H says teams may pursue long-lasting, load-bearing replacement joints built from a patient's own cells, one of three areas in its program. \[2\]
- **Regulation.** The registered study is a safety evaluation of a wound matrix after skin cancer surgery, not a test of cartilage or bone regrowth. \[4\] The sources opened do not describe a regulatory route for joint repair.
- **Capital and scale-up.** The two companies named report $12 million (Series A) and $11.3 million (total raised), and the sources opened give no cost of manufacture. \[3\]\[5\]

### Data sources

- **NIH RePORTER and NIBIB program pages**, for grants. \[6\]\[1\]
- **ARPA-H awards page**, for NITRO performers. \[7\]
- **ClinicalTrials.gov**, for early studies. \[8\]
- **FDA device databases**, for 510(k), De Novo and PMA records. \[9\]
- **Company pages**, as company claims. Funding figures come from trade press and are not in a single registry; SEC Form D filings could confirm private raises. \[10\]

### Changelog

- 2026-11-18: First published.

### Sources

1. NIBIB, "Physiomimetic Materials", program page (agency statement). [nibib.nih.gov](https://www.nibib.nih.gov/programs/physiomimetic-materials?ref=acentricresearch.com) (accessed 2026-11-18)
2. ARPA-H, "ARPA-H launches program to help joints heal themselves" (NITRO program launch), 2023-05-18 (agency statement). [arpa-h.gov](https://arpa-h.gov/news/nitro/?ref=acentricresearch.com) (accessed 2026-11-18)
3. Pulse 2.0, "Tempo Therapeutics: Tissue Engineering And Regenerative Medicine Raises $12 Million", 2024-03-21 (trade press reporting a company announcement). [pulse2.com](https://pulse2.com/tempo-therapeutics-tissue-engineering-and-regenerative-medicine-raises-12-million?ref=acentricresearch.com) (accessed 2026-11-18)
4. ClinicalTrials.gov, NCT06600152, "Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds" (registry record; sponsor query "Tempo Therapeutics", API v2). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06600152?ref=acentricresearch.com)(accessed 2026-11-18)
5. Northwestern University RENU, industry spotlight page, entry of 2026-01-12 on Nanochon, relaying an Entrepreneur News Network report (secondary relay of a company announcement). [renu.northwestern.edu](https://renu.northwestern.edu/news-events/industry-spotlight/index.html?ref=acentricresearch.com)(accessed 2026-11-18)
6. NIH RePORTER, project search. [reporter.nih.gov](https://reporter.nih.gov/?ref=acentricresearch.com) (listed as a data source, not opened for this Brief)
7. ARPA-H, funding awards page. [arpa-h.gov](https://arpa-h.gov/explore-funding/awards?ref=acentricresearch.com) (listed as a data source, not opened for this Brief)
8. ClinicalTrials.gov, study search. [clinicaltrials.gov](https://clinicaltrials.gov/?ref=acentricresearch.com) (listed as a data source; opened through its API only for two sponsor queries, 2026-11-18; not searched for this Junction)
9. FDA De Novo database (the 510(k) and PMA databases are on the same site). [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ref=acentricresearch.com) (listed as a data source, not searched for this Brief; the two De Novo documents cited were opened as PDFs)
10. SEC EDGAR, full-text search. [sec.gov](https://www.sec.gov/edgar/search/?ref=acentricresearch.com) (listed as a data source; one exhibit was opened by its archive address, and the search itself was not run for this Brief)